Robert Whitehead is a seasoned bioscience entrepreneur with a track record of building high-value pharmaceutical companies and delivering strong investor returns, including two exits with 11x and 18x multiples. He is the Founder and Executive Chairman of Continuity Biosciences, established in 2024, following the acquisition of a portfolio of drug delivery technologies from Houston Methodist Hospital.

Bob is also Chairman and Co-Founder of Sprout Pharmaceuticals, and previously served as Co-Founder and CEO of Slate Pharmaceuticals, which was acquired in 2011. Known for identifying and unlocking value in underutilized assets, he has led multiple strategic transactions resulting in exits totaling hundreds of millions to over a billion dollars.

He is a seed-stage investor and advisor to several healthcare startups and recently served as CEO of Isleworth Healthcare Acquisition Corp.